$10 Billion Deal, page-12724

Just cant see a cr before results and not convinced there will be one.

I think caspex? Has a point re total t/o potentially being unnactractive as it currently would need a purchaser to bid very aggressively for unknown broadspsctrum viabilty ... but given (reality is footmax) that even on successful hiv alone the valuations referred to on these threads look low.

Is there a middle ground?

Lump sum upfront, licence hiv, fund ph3 or get it to market on some fast track (look at prelim results in detail before you argue ignorantly pls folks) , rev share to BIT.

BIT free to develop balance and obviously send lux and max and wb Christmas cards?

struggling to see issue strategically.

i mocked up a pricing model based on longer than 6 months treatment for hiv. Shorter for covid and ancillary.

I cant see too many issues with licensing/ branding / pricing disparity ino

dyor